Cost-sharing Requirements for Insulin and Diabetes Supplies
The implementation of H0367 is expected to significantly reduce the financial burden on individuals relying on insulin and diabetic supplies for their health management. By imposing these limits, the bill aims to ensure that more people have better access to necessary medications and supplies without facing exorbitant out-of-pocket costs. This could positively affect health outcomes for individuals with diabetes, making essential care more affordable and accessible.
House Bill H0367 aims to regulate the cost-sharing requirements associated with insulin and diabetes supplies by capping the maximum out-of-pocket expenses that health insurance policies can impose on insured individuals. Specifically, the bill establishes a limit of $35 for a 30-day supply of insulin, regardless of the type or quantity, and sets a cap of $100 for a 30-day supply of various diabetes supplies such as blood-glucose test strips and syringes. This legislation would take effect on July 1, 2026, applying to all health insurance policies in Florida delivered, issued, renewed, or amended after this date.
Notably, the bill has generated discussions regarding its implications for insurance providers and the potential impact on premiums. Supporters argue that the bill will help those affected by diabetes manage their costs more effectively and lead to better health outcomes due to improved access to necessary supplies. Conversely, some critics may express concerns about the implications for insurance market stability and the affordability of coverage overall if insurers are compelled to absorb these costs.